These studies suggest a role for BRAF and KIT driver mutations as well as key players of the mitotic cycle on the dysregulation of mechanisms that lead to aneuploidy across melanoma subtypes, and therefore prompt the need for further scrutiny into treatment options in the context of aneuploid disease. This evidence concerns the gene BRAF and melanoma.